Sign In
Buy GRF
$10.08
-0.370 (-3.54%)
At Close: Jul 31, 2026
How to buy Sims shares | 18 May price A$6.44 | Finder
09:33am, Thursday, 14'th May 2020
Ever wondered how to buy shares in Sims? We explain how and compare the best share trading platforms. Latest Sims share price is A$6.44.
A comprehensive guide of the best video games to play during lockdown
12:54pm, Thursday, 26'th Mar 2020
As the world slips further into what feels like a sci-fi dystopian novel, complete with lockdowns and numbered trips outdoors, people need an escape from the harsh realities of life more than ever. Th
Grifols PharmacyKeeper ranked No. 1 in KLAS rating, extends category leadership
02:00pm, Thursday, 13'th Feb 2020
Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announce
Better Lithium-Ion Batteries Possible With Nanoscale Molecular View of Self-Assembling Structure
03:13pm, Thursday, 06'th Feb 2020
Scientists Learn More about the First Hours of a Lithium-ion Battery’s Life The first hours of a lithium-ion battery's life largely determine just how well it will perform. In those moments, a set o
Eagle Capital Growth Fund Finalizes Year-End Distribution of $0.56 Per Share
10:00pm, Thursday, 26'th Dec 2019
Eagle Capital Growth Fund Finalizes Year-End Distribution of $0.56 per Share
10 Reasons Why The Sims 4 Remains Insanely Popular 5 Years After Launch
02:00pm, Saturday, 14'th Dec 2019
Five years after its release, The Sims 4 continues to grow even more popular. Here are 10 reasons why it has been such a breakout success./
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
02:24pm, Thursday, 12'th Dec 2019
Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin sub
Grifols presents its latest Alzheimer's clinical trial data
08:42pm, Friday, 06'th Dec 2019
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging results of its AMBAR (Alzheimer Management by Album
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements
03:26pm, Thursday, 05'th Dec 2019
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today an
Grifols to present latest Alzheimer's clinical trial results
02:17pm, Monday, 02'nd Dec 2019
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzh
Eagle Capital Growth Fund Declares Year-End Distribution of $0.56 Per Share
09:46pm, Thursday, 07'th Nov 2019
Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.56 per share. Consistent with recent historic practice, the Fund will pay the distributi
Grifols introduces AlphaID™, a free cheek swab to screen for Alpha-1, the most common genetic form of COPD
03:00pm, Thursday, 07'th Nov 2019
BARCELONA, Spain, Nov. 7, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnos
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of CPV Power Plant No.1 Bond SPV (RF) Limited and other ratings that are associated with the same analytical unit.
